|
APEC1621B
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations |
Open |
|
APEC1621D
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors |
Open |
|
APEC1621F
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations |
Open |
|
APEC1621G
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations |
Open |
|
APEC1621I
|
NCI-COG Pediatric Match(MOLECULAR ANALYSIS FOR THERAPY CHOICE)-Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes |
Open |
|
E1A11
|
Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) |
Open |
|
EAY131
|
Molecular Analysis for Therapy Choice (MATCH) |
Open |
|
HO07403
|
A Longitudinal Study to Evaluate Changes in Cellular Protein Expression and Activation in Bone Marrow Tumor Cells and Stromal Cells from Patients with Multiple Myeloma |
Open |
|
UW13056
|
Women's Integrative Sexual Health (WISH) Program Research Database |
Open |
|
UW15106
|
Genomic Analysis of Long-Term Survivors with Metastatic Cancer |
Open |
|
UW16004
|
Phase Ib Trial of Pembrolizumab in Combination with Dinaciclib in Subject with hematologic Malignancies |
Open |
|
UW16059
|
Patient-related Barriers to Pain Management: Revisiting the Pain Barriers Questionnaire |
Open |
|
UW16128
|
A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients-the INSIGHT-MM study
|
Open |
|
UW16139
|
A Pilot Study to Evaluate the Therapeutic Response of Tumor Cells Co-cultured with Non-tumor Cells from Patients with Multiple Myeloma ex vivo
|
Open |
|
UW17038
|
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) |
Open |
|
UW17096
|
Improving Survivorship Care Planning for Bone Marrow Transplant Survivors: A Sociotechnical Systems Approach
|
Open |
|
UW17120
|
An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA)
|
Open |
|
UW17136
|
A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma
|
Open |
|
UW17144
|
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants with Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
|
Open |
|
UW17147
|
Pre-Visit Planning in Palliative Care |
Open |
|
UW17156
|
Analysis of the Gut Microbiome in Patients Undergoing Autologous PBSCT and Lenalidomide Maintenance for Multiple Myeloma |
Open |
|
UW17157
|
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma |
Open |
|
UW18015
|
A Phase I/II Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma |
Open |
UW Carbone
